10108329A feasibility study to test the novel Tutti Toot Trumpet's musically gamified dysfunctional breathing retraining course for asthmatic children. Tutti Toot Trumpet has UK Patent Granted.ClosedCollaborative R&DInnovate UKAsthma is the most common chronic lung disease in UK children with 1.1 million receiving treatment. Asthma costs the UK economy £1.1Billion/year. Hospital admissions £86 million/year, 75% of these are avoidable. The National Review of Asthma Deaths states 90% of childhood deaths are preventable. National Institute for Health and Care (NICE) guidelines recommend physiotherapy for asthmatic children, particularly diagnosing and retraining breathing pattern disorders (BPD). BPD 'mimics' asthma symptoms (coughing, wheezing, breathlessness, chest pain). During an NIHR i4i FAST project (2023), Tutti Toot extensively interviewed respiratory consultants and physiotherapists from children's hospitals in Manchester, Sheffield and Liverpool's Alder Hey, learning that clinicians struggle to accurately assess breathing patterns remotely. Primary school children struggle to perform breathing exercises without in-person help. Physios have difficulty in engaging the child with interventions in-clinic and at home. Tutti Toot Trumpet (TTT) is globally unique; offering primary school-aged children with respiratory diseases, a device which gamifies airway clearance(ACT)/BPD retraining, lung function measurements at home and making physiotherapy fun through musical engagement, similar to Sony Playstation's 'Guitar Hero'!. TTT has received three NIHR i4i awards and developed:? * TTT prototypes/mouthpieces.? * Clinician facing app to remotely monitor patient TTT breath and adherence data. * Patient app; musically gamifying ACT, BPD retraining, Peak Expiratory Flow Rate(PEFR) measuring, recording patients' daily therapy use in a home monitoring diary. * Value proposition, to meet the needs of childhood asthma and other chronic respiratory diseases, During extensive Patient Public Involvement (PPI) workshops, children with respiratory diseases said TTT was 'fun to use', 'improved lung function tests'. Our aims will be to test feasibility and de-risk the TTT, providing a concrete development step with the following outputs: Musically gamified dysfunctional breathing retraining course: * Develop a programme of musical games, with differing inhalation/exhalation ratios. Develop TTT's ability to stratify patient PEFR readings. * Inputting the patient's statistics into the clinician app, will display if the patient is either inside, above or under their predicted peak flow level. Work with National Institute for Health and Care Excellence (NICE) * Utilise Medtech Early Technical Assessment (META) Tool, to further validate feasibility, requirements and understand the evidence we will need to collect.